Merrill Lynch Callable & Exch Notes 0.25% Basket of Pharm Stock 4/27/06 (MLD.A*)
AMEX · · CUSIP 59018S2T0
This security is no longer trading as of 4/27/2006.
The reference information below — security type, terms, ratings and company profile — is retained for research. Current pricing is not available.
Price History•••••
Final Price•••.••
Historical Chart•••••
Free registration unlocks the full price history and chart for MLD.A*, plus the quote, yields and fundamentals for every actively traded security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Special Product - Company Based
CUSIP
59018S2T0
Market Cap
Micro Cap · $21 Million
IPO
4/27/1999 · $1000.00/share
Parent Company
Merrill Lynch & Co., Inc. (MER)
Business: Merrill Lynch & Co., Inc., Medium-Term Notes, Series B, 0.25% Callable and Exchangeable Stock Portfolio-Linked Notes, issue price $1,094.39 per note, due 4/27/2006, linked to the performance of the common stock of Pfizer Inc., Sepracor Inc. and Warner-Lambert Co. The notes pay distributions of 0.25% per annum semi-annually on 4/27 & 10/27. The notes are redeemable for cash at the issuer's option on or after 4/28/2002 and exchangeable for cash any time on or after 6/30/1999 at the holder's option. At maturity or when called by the issuer, the holder will receive the greater of $1000 or the sum of the products for each portfolio security of the applicable share multiplier times the average price of the common stocks immediately prior to the redemption or maturity date. If exchanged by the holder, the holder will receive the greater of $1000 or the sum of the products for each portfolio security of the applicable share multiplier times the price of the common stocks on the day following the receipt of the exchange notice. The initial share multiplier are 2.2352 for Pfizer, 2.8383 for Sepracor and 4.1433 for Warner-Lambert. See the IPO Prospectus for further information on the notes and the exchange and redemption provisions by clicking on the ‘Link to IPO Prospectus’ provided below.

Company Contact

CEO
David H. Komansky
CFO
Thomas H. Patrick
Headquarters
4 World Financial Center, North Tower, New York, NY 10080
Phone
212-449-1000 · Toll-Free 800-637-7455
Fax
212-236-4384
Investor Relations
866-607-1234 · investor_relations@ml.com
Email Form
Contact Form »
SEC EDGAR Filings
View filings »